Paoletta S, Steventon G B, Wildeboer D, Ehrman T M, Hylands P J, Barlow D J
Pharmaceutical Science Division, King's College London, Franklin Wilkins Building, 150 Stamford Street, London SE19NH, United Kingdom.
Bioorg Med Chem. 2008 Sep 15;16(18):8466-70. doi: 10.1016/j.bmc.2008.08.034. Epub 2008 Aug 19.
Random Forest screening of the phytochemical constituents of 240 herbs used in traditional Chinese medicine identified a number of compounds as potential inhibitors of the human aromatase enzyme (CYP19). Molecular modelling/docking studies indicated that three of these compounds (myricetin, liquiritigenin and gossypetin) would be likely to form stable complexes with the enzyme. The results of the virtual screening studies were subsequently confirmed experimentally, by in vitro (fluorimetric) assay of the compounds' inhibitory activity. The IC-50s for the flavones, myricetin and gossypetin were determined as 10 and 11 microM, respectively, whilst the flavanone, liquiritigenin, gave an IC-50 of 0.34 microM--showing about a 10-fold increase in potency, therefore, over the first generation aromatase inhibitor, aminoglutethimide.
对240种中药中植物化学成分进行随机森林筛选,确定了一些化合物为人类芳香化酶(CYP19)的潜在抑制剂。分子建模/对接研究表明,其中三种化合物(杨梅素、甘草素和棉黄素)可能与该酶形成稳定复合物。随后通过对这些化合物抑制活性的体外(荧光)测定,对虚拟筛选研究结果进行了实验验证。黄酮类化合物杨梅素和棉黄素的半数抑制浓度(IC-50)分别测定为10微摩尔和11微摩尔,而黄烷酮甘草素的IC-50为0.34微摩尔,因此其效力比第一代芳香化酶抑制剂氨鲁米特高约10倍。